North East and North Cumbria
ICS Formulary
ICS Formulary
5 Infections
05-03-06 COVID-19 therapeutics
| Nirmatrelvir and Ritonavir Paxlovid® |
|
Formulary
|
|
 NICE TA878: Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 |
|
| Sotrovimab Xevudy® |
|
Formulary
|
|
|
NICE TA878: Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 |
|
|
| Molnupiravir Lagevrio® |
|
Restricted
|
|
|
| Casirivimab with Imdevimab Ronapreve® |
|
Non Formulary
|
|
|
Links
- COVID-19 Therapeutic Alert
- Interim Clinical Commissioning Policy: Antivirals or neutralising monoclonal antibodies in the treatment of COVID-19 in hospitalised patients (Version 5 - effective from 10th February 2022)
- NICE NG15: Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use
- NICE NG188: COVID-19 rapid guideline: managing the long-term effects of COVID-19
- NICE NG191: COVID-19 rapid guideline: managing COVID-19
- NICE NG63: Antimicrobial stewardship: changing risk-related behaviours in the general population
- NICE TA878: Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- NICE TA878: Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- North of Tyne, Gateshead and North Cumbria - Antibiotic and Diagnostic quick reference tools
- Primary Care Antimicrobial Guidelines
- TEWV: Antibiotic Prescribing Procedure
- UK Interim Clinical Commissioning Police - Therapies for patients with symptomatic hospital-onset COVID-19